Predict your next investment

ELECTRONICS | Technical & Scientific Instrumentation
polarean.com

See what CB Insights has to offer

Founded Year

2011

Stage

Loan | Alive

Total Raised

$2.68M

Last Raised

$250K | 1 yr ago

Revenue

$0000 

About Polarean

Polarean is commercializing hyperpolarized gas MRI technology, to enable academic institutions and industry scientists to pursue ideas and applications in basic physics, chemistry, or clinical imaging.

Polarean Headquarter Location

2500 Meridian Parkway Suite 175

Durham, North Carolina, 27713,

United States

919-206-7900

Latest Polarean News

Antimicrobial therapy fails to improve hospitalization, death in adults with IPF

Jun 8, 2021

Disclosures: Martinez reports he served on COPD advisory boards for AstraZeneca, Bayer, Boehringer Ingelheim, Chiesi, CSL Behring, Gala, GlaxoSmithKline, Novartis, Polarean, ProterixBio, Sanofi/Regeneron, Sunovion, Teva and Verona; served on COPD steering committees for AstraZeneca, GlaxoSmithKline, Chiesi and Sanofi; served on ILD advisory boards for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Bridge Biotherapeutics, CSL Behring, DevPro, Genentech, IQVIA, Sanofi, Shionogi, twoXAR, United Therapeutics, Veracyte and Zambon; served on ILD steering committees for Afferent/Merck, Bayer, Biogen, Boehringer Ingelheim, Gilead, Patara/Respivant, Promedior/Roche and Veracyte; served on safety and monitoring boards for Biogen, Boehringer Ingelheim, NHLBI, Roche/Genentech, Pulmonary Fibrosis Foundation, Nitto Denko, FibroGen and Galapagos; and received personal fees from Boehringer Ingelheim, Roche/Genentech and Veracyte. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio The addition of co-trimoxazole or doxycycline to usual care did not significantly improve time to respiratory hospitalization or death in adults with idiopathic pulmonary fibrosis, according to results of the CleanUP-IPF trial. “Although initial randomized trial data suggested improved outcomes with co-trimoxazole (trimethoprim-sulfamethoxazole) therapy in patients with fibrosing interstitial lung diseases, a large placebo-controlled trial failed to document an improvement in clinical outcomes with this agent. Preliminary data suggested that doxycycline can improve outcomes and inhibit metalloproteinases in patients with IPF,” Fernando J. Martinez, MD, MS, chief of the pulmonary and critical care medicine division at NewYork-Presbyterian Hospital/Weill Cornell Medicine, and colleagues wrote in JAMA. “Because antimicrobial therapy has been suggested to favorably alter the lung microbial community in other chronic disorders, this study was designed to address the hypothesis that an antimicrobial therapeutic strategy, with either co-trimoxazole or doxycycline, reduces the risk of nonelective respiratory hospitalization or death among patients with IPF .” Source: Adobe Stock. The pragmatic, randomized, unblinded CleanUP-IPF trial included 513 patients (mean age, 71 years; 23.6% women) with IPF. Patients were randomly assigned from August 2017 to June 2019 to receive usual care plus antimicrobial therapy (n = 254) or usual care alone (n = 259). The antimicrobials used in this study were co-trimoxazole (trimethoprim 160 mg/sulfamethoxazole 800 mg) twice daily plus folic acid 5 mg daily (n = 128) or doxycycline 100 mg once daily for those weighing less than 50 kg or 100 mg twice daily for those weighing at least 50 kg (n = 126). The primary endpoint of the CleanUP-IPF trial was time to first nonelective respiratory-related hospitalization or all-cause mortality. The trial was terminated in December 2019 due to futility. During a mean follow-up of 13.1 months, 108 primary endpoint events occurred; of those, 52 events (20.4 events per 100 patient-years) occurred in the usual care plus antimicrobial therapy group vs. 56 events (18.4 events per 100 patient-years) in the usual care group, with no significant differences between the groups (adjusted HR = 1.04; 95% CI, 0.71-1.53; P = .83). The researchers reported no significant interaction between the effect of the prespecified antimicrobial agent on time to first nonelective respiratory-related hospitalization or all-cause mortality in the co-trimoxazole group (aHR = 1.15; 95% CI, 0.68-1.95) vs. the doxycycline group (aHR = 0.82; 95% CI, 0.46-1.47; P = .66). The most common serious adverse events in patients assigned usual care plus antimicrobials vs. usual care included respiratory events (16.5% vs. 10%) and infections (2.8% vs. 6.6%). Researchers observed higher rates of diarrhea (10.2% vs. 3.1%) and rash (6.7% vs. 0%) among those assigned usual care plus antimicrobial therapy compared with those assigned usual care alone. According to the researchers, these findings extend upon results from the EME-TIPAC study, which suggested that a broad antimicrobial therapy strategy was not effective for improving clinical outcomes. “These findings do not support treatment with these antibiotics for the underlying disease,” the researchers wrote. Read more about

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Polarean

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Polarean is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

7,528 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Polarean Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Polarean Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.